Development and Validation of Algorithms for Systemic Sclerosis Identification in Electronic Health Record Data. [PDF]
ACR Open RheumatolObjective The aim of this study was to develop and validate International Classification of Diseases (ICD) code–based algorithms for identifying systemic sclerosis (SSc) cases within electronic health record (EHR) data and to evaluate algorithm performance. Methods We identified patients with at least one ICD, Ninth Revision (ICD‐9)/ICD‐10 code for SSc
Ozen G, O'Rorke M, Romitti P, Domsic R.
europepmc +2 more sources
Clinical Case Reports (discontinued), 2020 Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed
Hninyee Win
exaly +2 more sources
Hyalase in Dermatology: Applications Beyond Filler Management. [PDF]
J Cosmet DermatolABSTRACT Background Hyaluronic acid (HA) is a key extracellular matrix component in the skin. Hyaluronidase is an enzyme that breaks down HA into monosaccharides. The FDA has approved this enzyme for hypodermoclysis, drug absorption enhancement, and subcutaneous urography.
Hasanzadeh S +6 more
europepmc +2 more sources
Clonal disorders of clinical significance. A concept with important therapeutic implications. [PDF]
J Eur Acad Dermatol VenereolJournal of the European Academy of Dermatology and Venereology, Volume 39, Issue 5, Page 891-892, May 2025.
Lipsker D.
europepmc +2 more sources
Treatment of a Complex Case of Scleromyxedema Using a Novel Intravenous Immunoglobulin Preparation [PDF]
Case Reports in DermatologyIntroduction: We provide a case report on a patient with scleromyxedema treated with high-dose intravenous immunoglobulins (IVIgs) who reported less fatigue and fewer headaches after transitioning to Yimmugo, a novel IVIg preparation. Scleromyxedema is a
Anastasia Sophie Vollmer +3 more
doaj +2 more sources
Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and literature review [PDF]
Frontiers in Medicine, 2023 Lichen myxedematosus (LM) is an idiopathic cutaneous mucinosis disorder, and monoclonal gammopathy of undetermined significance (MGUS) is a preneoplastic plasma cell disease with a monoclonal increase in globulin.
Hua Huang, Shen-Xian Qian
doaj +2 more sources
Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. [PDF]
J Eur Acad Dermatol VenereolIn severe forms of monoclonal gammapathy associated with scleromyxoedema with dermatoneuro syndrome and/or cardiac involvement, deep and durable responses allowing IVIG withdrawal could be achieved using anti‐plasma cell therapy, including Imids, anti‐CD38 or proteasome inhibitors. Abstract Background Scleromyxedema (SM) is a rare skin disorder related
Theves F +12 more
europepmc +2 more sources
Scleromyxedema: An atypical case
Indian Journal of Dermatology, 2015 Scleromyxedema is a rare, chronic and persistent idiopathic disorder characterized by a generalized papular eruption due to dermal mucin deposition with an increase in dermal collagen. Patients usually have associated paraproteinemia.
Emy Thomas +3 more
doaj +3 more sources
Acta Medica Iranica, 1996 Scleromyxedema is a rare, chronic, progressive, fibromucinous disorder of unknown etiology, characterized by lichenoid waxy papules and firm induration of skin of trunk, face, forearm and hands; fibroblast proliferation and mucin deposition in the upper ...
Z. Safaii Naraghi. +1 more
doaj +3 more sources
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion [PDF]
Dermatology Reports, 2023 Scleromyxedema (SMX), the generalized and sclerodermic form of lichen myxedematous (LM), is a chronic mucinosis characterized by cutaneous manifestation and several systemic comorbidities.
Gaia Fasano +3 more
doaj +2 more sources